Testing Early Versus Late Time-Restricted Eating for Blood Sugar in Prediabetes
Compares early and late daily eating windows in adults with prediabetes or type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Precise Eating Time to Improve Glycemic Control and Cardiometabolic Health in Prediabetes and Diabetes
Key facts
- Where
- Nuthetal, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07171281, who can take part
Where in Germany
- German Institute of Human Nutrition Potsdam-RehbrueckeNuthetal, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- German Institute of Human Nutrition
- Trial code
- NCT07171281
- Record updated
- 29 September 2026
- Original description
The objective of this study is to investigate the impact of hypocaloric time-restricted eating (TRE) at different day times (early versus late TRE) on glucose metabolism and other cardiometabolic parameters in individuals with overweight and with normal, or impaired glucose metabolism (prediabetes and type 2 diabetes). In addition, the study aims to elucidate the molecular mechanisms underlying these effects.Read full original descriptionShow less
Precise Eating Time to Improve Glycemic Control and Cardiometabolic Health in Prediabetes and Diabetes: the GLYCOTIME Trial
The objective of this study is to investigate the impact of hypocaloric time-restricted eating (TRE) at different day times (early versus late TRE) on glucose metabolism and other cardiometabolic parameters in individuals with overweight and with normal, or impaired glucose metabolism (prediabetes and type 2 diabetes). In addition, the study aims to elucidate the molecular mechanisms underlying these effects.
Inclusion: Overweight or obesity (BMI 25-40 kg/m²); Healthy glucose metabolism (fasting glucose <100 mg/dl and glucose after 2 hours OGTT <140 mg/dl); OR impaired glucose metabolism (fasting glucose 100-125 mg/dl and/or glucose after 2 hours OGTT 140-199 mg/dl and/or HbA1c 5.7-6.4%); OR type 2 diabetes (according to existing medical diagnosis or fasting glucose >126 mg/dl and/or glucose after 2 hours OGTT >200 mg/dl and/or HbA1c ≥6.5%); Daily eating window ≥12 hours.
Exclusion: Traveling across more than one time zone within one month prior to the study; Treatment with insulin, sulfonylureas, and GLP-1 receptor agonists, steroid use (oral, cutaneous, or parenteral), regular intake of melatonin, anticoagulation treatment that cannot be paused; Eating disorders, food intolerance/allergy to ingredients in the diet product, vegan diet, practicing time-restricted eating; Severe chronic illnesses or other conditions that are incompatible with the planned intervention and examination program (e.g. type 1 diabetes, recent cardiovascular event, malabsorption, cancer in the last two years, etc.); Weight changes > 5% within past 3 months; Shift work; Pregnancy and breastfeeding; Extreme early and extreme late chronotypes.